Squarepoint Ops LLC Boosts Position in Tarsus Pharmaceuticals, Inc. $TARS

Squarepoint Ops LLC boosted its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 78.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 102,642 shares of the company’s stock after purchasing an additional 44,986 shares during the quarter. Squarepoint Ops LLC owned about 0.24% of Tarsus Pharmaceuticals worth $4,158,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Tarsus Pharmaceuticals by 26.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company’s stock worth $66,000 after buying an additional 339 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Tarsus Pharmaceuticals by 220.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock worth $164,000 after acquiring an additional 2,782 shares in the last quarter. Quarry LP lifted its position in Tarsus Pharmaceuticals by 20.0% in the first quarter. Quarry LP now owns 3,599 shares of the company’s stock valued at $185,000 after acquiring an additional 599 shares during the last quarter. AlphaQuest LLC purchased a new stake in Tarsus Pharmaceuticals in the first quarter valued at $189,000. Finally, Allianz Asset Management GmbH acquired a new position in Tarsus Pharmaceuticals in the second quarter valued at $227,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Down 1.1%

Tarsus Pharmaceuticals stock opened at $80.48 on Tuesday. Tarsus Pharmaceuticals, Inc. has a twelve month low of $38.51 and a twelve month high of $85.25. The stock has a 50 day moving average of $74.41 and a two-hundred day moving average of $57.29. The company has a current ratio of 4.29, a quick ratio of 4.25 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $3.42 billion, a price-to-earnings ratio of -39.84 and a beta of 0.74.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 26.29% and a negative net margin of 22.17%.The business had revenue of $118.70 million for the quarter, compared to analyst estimates of $114.22 million. As a group, research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on TARS shares. The Goldman Sachs Group reiterated a “neutral” rating and set a $51.00 target price on shares of Tarsus Pharmaceuticals in a research report on Thursday, November 6th. HC Wainwright lifted their price target on Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the stock a “neutral” rating in a research report on Monday, October 20th. Mizuho started coverage on Tarsus Pharmaceuticals in a report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 price objective for the company. Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, Zacks Research raised shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $79.86.

Insider Buying and Selling

In other news, CEO Bobak R. Azamian sold 6,000 shares of the firm’s stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $55.37, for a total value of $332,220.00. Following the completion of the sale, the chief executive officer owned 812,106 shares in the company, valued at approximately $44,966,309.22. This trade represents a 0.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 8.97% of the company’s stock.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.